Guidance encouraging sponsors to use master protocols for coronavirus drug development also will influence US Food and Drug Administration policy on the clinical trial strategy going forward.
The FDA released a final guidance on 17 May as a COVID-19-focused document, which would remain in effect until the end of the public health emergency
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?